strontium-89

strontium-89

Radiation oncology A beta-emitting bone-seeking radioisotope–T1⁄2 50.4 days, used to manage pain in Pts with diffuse bone metastases–eg, with end-stage breast or prostate CA for whom pain medication may be ineffective
References in periodicals archive ?
The meeting provides an ideal location to meet with collaborators, vendors and partners working on the recently announced commercialization of Strontium-89 Chloride (Sr89).
Radionuclide therapy, in the form of systemic strontium-89 therapy, may be useful in the palliation of CRPC when multiple skeletal sites are involved in carefully selected patients.
Strontium-89 as an adjuvant to external beam radiation improves pain relief and delays disease progression in advanced prostate cancer: Results of a randomized controlled trial.
has detected strontium-89 and -90, which are highly toxic, from samples
becquerels of strontium-89 in soil collected on May 6 in Namie Town, 24 km
MEXT reported on measurements of strontium-89 (half-life: 50.
Since April 1998, the firm has been marketing cobalt-60, iridium-192, strontium-89, barium-133, and nickel-63.
Mitoxantrone chemotherapy in combination with glucocorticoids and the radioisotopes strontium-89 and samarium-153-lexidronam are now available.
There are now two FDA-approved radioactive pharmaceuticals called strontium-89 (Metastron[R]) and samarium 153-lexidronam (Quadramet[R]).
Radiologist Edward Silberstein of the University of Cincinnati Medical Center has been investigating a host of radionuclides with a natural affinity for bone, including samarium-153, strontium-89, and rhenium-186.
Strontium-89 is an intravenously administered cancer drug that provides long lasting pain relief for patients suffering from bone pain due to metastatic cancer, typically caused by advanced stage breast, prostate or lung cancer.
Strontium-89 has now entered a large-scale patient trial in 30 U.